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Figure 1. A Role for Zfp423 in Preadipocyte
Determination
(A) Zfp423 induces expression of the master regulator of
adipogenesis, PPARg, and commits cells to become prea-
dipocytes.
(B) PPARg acts in a feed forward loop with C/EBP factors
to maintain high expression of each other and to terminally
differentiate the cells into adipocytes.
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Previews(BAT), the major adipose compart-
ment during this developmental
stage. Zfp423 null mice displayed a
reducedmass of BAT and an increase
in connective tissue intrusions. More-
over, developing white adipocyte
precursor cells in the subcutaneous
region were strongly reduced in
Zfp423 null mice. In accordance with
the finding that Zfp423 was not
expressed in primary or C2C12 myo-
blasts, there was no obvious defect
in other mesodermal lineages, as
muscle and connective tissues ap-
peared normal in these embryos.
Tissue-specific or cell lineage-spe-
cific Zfp423 ablation will be required
to fully understand the physiologic
role of Zfp423.
Taken together, the findings pre-
sented by Gupta and colleagues
bridge an existing gap in our under-standing of adipocyte differentiation,
which has been largely focused on the
transition from preadipocytes to adipo-
cytes using established cell lines such as
the 3T3-L1 model. In this context, the
new work implicates the zinc finger
protein Zfp423 as a key factor to explainthe critical question of howprecursor cells
become fated for fat (Figure 1).
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Nutrients such as amino acids (aa) and glucose mediate mammalian target of rapamycin complex 1
(mTORC1) signaling to control cell growth andmetabolism. Recent studies (Yan et al., 2010) identify a contrib-
utor, PP2A phosphatase subunit PR613, in regulating the aa-sensitive input to mTORC1.The epidemic in obesity and associated
pathologies, including insulin resistance,
type 2 diabetes, cardiovascular disease,
and cancer (Calle and Kaaks, 2004), has
been fueled by nutrient overload driven
by the abundance, palatability, and low
cost of food (Finkelstein et al., 2005).
The intracellular serine-threonine kinasemTOR plays a critical role in mediating
these pathologies. The rapamycins (spe-
cific mTOR inhibitors) have been ap-
proved for treatment of renal cancers
(Houghton, 2010), and recent studies
show that they increase life span, possibly
through their ability to recapitulate the
effects of caloric restriction (Katewa andKapahi, 2010). mTOR is found in two
structurally and functionally distinct com-
plexes, mTORC1 and mTORC2. Although
both complexes are implicated in hor-
monal signaling mediated by class 1
phosphatidylinositide-3OH kinase (PI3K),
only mTORC1 is positively regulated by
nutrients, particularly aa and glucose. In, April 7, 2010 ª2010 Elsevier Inc. 245
Figure 1. Regulation of MAP4K3 by PP2A
Model for the role of PP2AT613 and MAP4K3 in nutrient signaling to mTORC1 (see text for details).
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Previewsthe absence of nutrients, mitogens and
hormones fail to activate mTORC1, but
not mTORC2. Thus, nutrients are essen-
tial agonists inmediatingmTORC1 activa-
tion (Avruch et al., 2009). Moreover, com-
ponents of the canonical PI3K signaling
pathway are not utilized in mTORC1 acti-
vation by nutrients (Nobukuni et al., 2005).
Instead, a distinct, dominant nutrient
signaling pathway converges with the
hormonal-PI3K signaling pathway to drive
growth at the level of mTORC1 (Um et al.,
2006).
Studies from different laboratories have
identified roles for the class 3 PI3K
(hVPS34), Ras-related guanosine triphos-
phatases (Rag GTPases), Ras homolog
enriched in brain (Rheb) GTPase, and
phospholipase D1 (PLD1) in nutrient
signaling to mTORC1 (Avruch et al.,
2009). In a previous report, Lamb and
colleagues identified MAP4K3, a Ste20-
related MAP4K, as a critical mediator of
aa-induced mTORC1 activation (Findlay
et al., 2007). Importantly, they demon-
strated that MAP4K3 activity is regulated
by aa availability but unaffected by insulin
or rapamycin, placingMAP4K3 upstream,
on the nutrient branch of the mTORC1
signaling pathway (Figure 1). This initial
report raised several questions, including
the mechanism by which aa mediate
MAP4K3 activation.
In work recently published in Mole-
cular Cell, Lamb and colleagues identify
PP2AT613 as a critical mediator of nutrient
signaling to mTORC1 via MAP4K3 (Yan
et al., 2010). Since many protein kinases
are themselves regulatedbyphosphoryla-246 Cell Metabolism 11, April 7, 2010 ª2010tion, Yan et al. have now asked whether
this is the case for MAP4K3 (Yan et al.,
2010). To this end, they performed mass
spectrometry phosphopeptide analysis
on purified, ectopically expressed
MAP4K3. Two phosphopeptides were
identified—one included phosphorylated
Ser170, from theMAP4K3 kinase domain.
Subsequent mutational analysis showed
this site to be critical for kinase activity.
The authors then generated an antibody
specific for phospho-Ser170, which did
not detect endogenous MAP4K3, but
did recognize inducible, ectopically ex-
pressed MAP4K3. Removal of aa from
the medium for 60 min eliminated Ser170
phosphorylation, a response that was
reversed within 15 min of aa readdition.
Importantly, Ser170 phosphorylation is
relatively unaffected by insulin treatment.
Coexpression of kinase-dead and wild-
type MAP4K3 as well as in vitro studies
indicated that Ser170 phosphorylation is
regulated by trans-autophosphorylation,
although such studies have not ruled out
a cis-autophosphorylation mechanism.
A further kinetic analysis revealed an
acute drop in Ser170 phosphorylation
within 5 min of aa depletion, suggesting
the potential involvement of a phospha-
tase. Treatment with the phosphatase
inhibitor okadaic acid at concentrations
thought to be selective for PP2A blocked
MAP4K3 Ser170 dephosphorylation fol-
lowing aa withdrawal. Consistent with
this finding, addition of PP2A to purified
MAP4K3 in vitro also led to Ser170
dephosphorylation. PP2A is a serine-
threonine phosphatase multiprotein com-Elsevier Inc.plex consisting of a structural subunit
(PP2A-A), a regulatory or targeting subunit
(PP2A-B), and a catalytic subunit (PP2A-
C). PP2A-B subunits are thought to be
critical for specific substrate recognition
(Eichhorn et al., 2009). Mass spectrome-
try analysis of exogenously expressed
MAP4K3 revealed that it bound to
PR613, a regulatory/targeting subunit of
PP2A. Immunoprecipitation and western
blotting analyses confirmed this associa-
tion. The authors then used both gain-of-
function and loss-of-function approaches
to investigate the role of PR613 in aa
signaling. Ectopic expression of PR613 in
the presence of aa led to inhibition of
MAP4KSer170 phosphorylation and inac-
tivation of mTORC1, as measured by
S6K1 phosphorylation. In parallel, shRNA
depletion of PR613 protein levels pro-
tected MAP4K Ser170 phosphorylation
under conditions of aa deprivation.
Consistent with these findings, depletion
of PR613 also protected mTORC1 sig-
naling, as measured by S6 240/244 phos-
phorylation in the absence of aa. Finally,
depletion of PR613 resulted in an increase
in cell size, a phenotype tightly linked to
increased mTORC1 signaling.
The authors initially hypothesized that
aa decrease Ser170 phosphorylation by
activating PP2A via the PR613. However,
in vitro PP2A phosphatase activity is the
same regardless of whether it is assayed
from cells deprived of, or stimulated by,
aa. The authors then determined whether
binding of PR613 to MAP4K3 was regu-
lated by aa by employing pull-downs
with two different baits: microcystin
agarose, which specifically binds to the
PP2A catalytic subunit, or PR613. In
both analyses, they found that aa depriva-
tion induced an increase in the associa-
tion of PP2A with MAP4K3. Moreover,
an amino-truncated MAP4K3 (aa 1–431),
which binds less well to PP2A, retained
activity following aa depletion. Thus, the
results support a model in which binding
of PP2A to MAP4K3 is essential for the
regulation of MAP4K3 by aa (Figure 1).
This study has shown that PP2AT613
(PR613 containing PP2A complex) is crit-
ical for MAP4K3 and mTORC1 regulation
by aa (Figure 1). However, some ques-
tions about the PP2AT613 and mTORC1
regulation still remain. The authors have
shown that S6 phosphorylation is pro-
tected from aa depletion in the absence
of PR613. However, it is yet to be
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Previewsdetermined whether phosphorylation of
S6K1 and 4E-BP1, direct substrates of
mTORC1, are protected as well. This is
an important issue, as PP2A is known to
directly interact with S6K1 (Peterson
et al., 1999). In addition, looking ahead,
it would be of interest to address whether
other nutrients, particularly glucose, also
mediate MAP4K3 activity via PP2AT613.
What is the mechanism by which
increased MAP4K3 mediates mTORC1
activation? Recent studies have shown
thatRagGTPases are critical components
in mediating aa-induced mTORC1 activa-
tion (Avruch et al., 2009). In the absence of
Rag GTPases, ectopic expression of
MAP4K3 failed to increase mTORC1 acti-
vation, prompting the authors to suggest
that Rag GTPases act downstream of
MAP4K3. However, this does not ex-
clude the possibility of a parallel pathway
or even that Rag GTPases regulate
MAP4K3 activity, as in the absence of
Rag GTPases, ectopically expressed
MAP4K3 may be inactive. The authors
do not detect binding of Rag GTPases to
MAP4K3, nor do the Rag GTPases serve
as an in vitroMAP4K3 substrate. Analyses
of Rag GTP loading and the ability of Rags
to bind to mTORC1 upon ectopic expres-
sion or depletion of MAP4K3 would yield
amore definitive picture of the relationship
between MAP4K3 and the Rag GTPases.In addition, a deeper understanding of
the interplay between MAP4K3, Rags,
hVPS34, and PLD1 will be critical in
elucidating the underlying mechanisms
by which nutrients control mTORC1 sig-
naling.
Recent studies suggest that PP2A
acts as a tumor suppressor (Eichhorn
et al., 2009). Moreover, hyperactivation
of mTORC1 signaling activates a negative
feedback loop from S6K1, which acts to
suppress insulin signaling, leading to
insulin resistance (Um et al., 2006). The
mTORC1 signaling pathway may be a
critical target of PP2A in suppressing
both tumorigenesis and insulin resis-
tance. Identifying the direct target of
MAP4K3 inmediating mTORC1 activation
and understanding the mechanisms by
which aa affect the association of PR613
and MAP4K3 would aid in assessing the
potential of these components as thera-
peutic targets for the treatment of cancer
and type 2 diabetes.ACKNOWLEDGMENTS
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